Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Proportion of Patients With Adverse Events
研究概览
简要总结
The objective of this non-interventional study is to evaluate the safety of Aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic uticaria. The patients will receive 2.5 ml (1.25 mg) once daily.
详细描述
Pediatric patients aged 1-5 years
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with allergic rhinitis or chronic idiopathic urticaria
- •Aged 1-5 years old
- •Caregiver's consent to participate
排除标准
- •Healthy individuals
- •Younger or older than the 1-5 year old age range
研究组 & 干预措施
Pediatric Patients
Those with allergic rhinitis or chronic idiopathic urticaria.
干预措施: Desloratadine (Drug)
结局指标
主要结局
Proportion of Patients With Adverse Events
时间窗: Follow-up visit at 3 - 5 weeks after treatment initiation
An adverse event is any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, whether or not considered related to the use of that product. This includes the onset of new illness and the exacerbation of pre-existing conditions.
次要结局
未报告次要终点